A pharmaceutical composition for treating endometriosis
By using a specific combination of curcumin, EGCG, and pterostilbene, co-delivery liposomes and nanostructured liposomes are formed, which solves the problems of high recurrence rate and severe side effects of endometriosis and achieves a highly effective and low-toxicity treatment effect.
Patent Information
- Application Number
- CN202511434104.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-09
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-10-09
AI Technical Summary
Current treatments for endometriosis suffer from high recurrence rates, significant side effects, and difficulty in simultaneously reversing the vicious cycle of hormonal imbalance, immune dysregulation, and stem cell activation.
A drug composition consisting of curcumin, epigallocatechin gallate (EGCG), and pterostilbene in a specific ratio is used to improve bioavailability through co-delivery of liposomes and nanostructured liposomes, and to synergistically target and inhibit estrogen synthesis, cell migration, and proliferation.
It significantly improves the solubility and stability of the drug, enhances the therapeutic effect on endometriosis, reduces the recurrence rate and side effects, and provides a highly effective and low-toxicity treatment strategy.
Smart Images

Figure CN120899698B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a pharmaceutical composition for treating endometriosis, belonging to the field of pharmaceutical technology. Background Technology
[0002] Endometriosis (EMs), also known as endometriosis, refers to the appearance, growth, and infiltration of endometrial tissue (glandules and stroma) in the uterine cavity and other areas outside the uterus, causing recurrent bleeding and subsequently leading to pain, infertility, nodules, or masses. EMs is a common and prevalent disease among women of reproductive age, characterized by widespread lesions, diverse morphologies, high invasiveness and recurrence, and a sex hormone dependence.
[0003] The occurrence of endometrial ectopic uterine tissue (EMs) is related to factors such as sex hormones, immunity, inflammation, and genetics, but its pathogenesis remains unclear. Currently, several theories exist, with the retrograde menstrual flow implantation theory being the dominant one. This theory posits that menstrual blood flows retrogradely into the pelvic endometrium, where it implants and grows through adhesion, invasion, and angiogenesis. The situ endometrial determinism theory emphasizes that the characteristics of the patient's own situ endometrium (such as abnormal inflammatory response, hormone hypersensitivity, and strong invasive / angiogenic capacity) are the determining factors, making it easier for exfoliated cells to colonize ectopically. Other theories, including the coelomic metaplasia theory, the angiogenesis and lymphatic metastasis theory, and the stem cell theory, all suggest that the occurrence and development of ectopic endometrial tissue are closely related to the level of inflammation, hormone stimulation, immune escape, or excessively enhanced proliferation and differentiation capacity. These theories, to varying degrees, provide key theoretical directions for the diagnosis and treatment of EMs. The specific mechanisms are summarized below: First, as a hormone-dependent disease, estrogen is widely recognized as promoting the occurrence and development of endometriosis (EMs). Multiple estrogen-related genes, such as STAR, CYP19A, and 17β-HSD2, are closely associated with its development. Progesterone and its different receptor subtypes (PR-A and PR-B) are also related to the occurrence of EMs. Progesterone resistance is one of the important characteristics of the pathogenesis of endometriosis. Gene expression analysis of EMs patients suggests that different subtypes of progesterone resistance exist in EMs patients, and their susceptibility to the disease is related to genes such as FOXO1A, MIG6, and CYP26A1.
[0004] Similarly, endometriosis (EM) is also a systemic autoimmune disease characterized by local inflammation and immune dysregulation in endometriotic lesions. Inflammation and its secondary fibrosis can lead to a range of clinical manifestations, including pelvic pain, digestive and urinary symptoms, and infertility. Studies have found significantly elevated levels of inflammatory factors such as TNF-α, IL-4, IL-6, IL-10, and IL-1β in the peritoneal fluid of patients. RANTES, IL-1β, MIF, and TNF-α are also increased in ectopic lesions. Abnormal expression of these factors may cause local immune imbalance in the lesions, leading to immune tolerance and promoting the growth of ectopic lesions. Immune cells such as macrophages and thymus-dependent lymphocytes, and the inflammatory mediators they secrete, all participate in the pathogenesis.
[0005] In addition, stem cell factors are also important influencing the pathogenesis of endometrial lesions (EMs). Neonatal uterine bleeding leads to the self-proliferation and differentiation of ectopic endometrial mesenchymal stem cells and endometrial epithelial progenitor cells under the activation of estradiol, promoting the occurrence and development of ectopic endometrial lesions. After puberty and menstruation, endometrial stem cells or progenitor cells flow retrogradely with the shed endometrium into the pelvic cavity, adhere to pelvic mesothelial cells, and grow, leading to the classic "retrograde menstruation theory" of EMs. Bone marrow-derived stem cell populations, including bone marrow mesenchymal stem cells, hematopoietic stem cells, and endothelial progenitor cells, may all be beneficial for endometrial regeneration. Bone marrow-derived stem cell populations can migrate to the endometrium or its ectopic lesions and differentiate into endometrial cells; therefore, bone marrow-derived stem cell populations are also one of the sources of ectopic endometrium.
[0006] The goal of endometriosis (EMs) treatment is to reduce and eliminate lesions, alleviate and eliminate pain, improve and promote fertility, and reduce and prevent recurrence. Treatment strategies can be broadly divided into surgical resection of lesions and drug therapy. International guidelines recommend surgical resection of all subtypes of endometriosis based on evidence that laparoscopic treatment improves condition-related pain compared to diagnostic laparoscopy alone at 6 months, and surgical resection is generally considered the best treatment for ovarian EMs. Drug therapy for EMs-related infertility typically follows two strategies: one is to inhibit follicle growth to induce amenorrhea, thereby inhibiting the development and growth of endometriosis lesions and improving subsequent fertility; the other is to stimulate follicle growth and ovulation. Initial treatment usually involves the use of combined oral contraceptives, which are effective in reducing pain and preventing postoperative recurrence. Hormone suppression therapy is routinely prescribed because there is evidence that steroids play a key role in the pathophysiology of EMs. Treatment is often considered if endometriosis is suspected in young women before surgical confirmation of the lesions, and is also provided postoperatively if symptoms do not improve or the disease recurs.
[0007] Although surgery and hormone therapy are widely used in the treatment of endometriosis (EMs), their limitations are becoming increasingly apparent. First, while surgical resection can eliminate lesions in the short term, it cannot block the stem cell-driven recurrence mechanism, resulting in a recurrence rate as high as 40-50% within 5 years. Second, hormone-suppressive therapies (such as oral contraceptives and GnRH agonists) rely heavily on the progesterone receptor pathway, significantly reducing their efficacy in progesterone-resistant patients, and long-term use can lead to side effects such as osteoporosis and vasomotor symptoms. Furthermore, existing drugs in immune / inflammatory modulation strategies rarely target the local immune escape microenvironment at the lesion site (such as M2 macrophage polarization and abnormal Treg cell activation). More importantly, current treatment strategies lack sufficient multi-mechanism synergistic intervention, and traditional single-therapies struggle to simultaneously reverse the vicious cycle of hormone imbalance, immune dysregulation, and stem cell activation. Summary of the Invention
[0008] Purpose of the invention: The technical problem to be solved by the present invention is to provide a pharmaceutical composition for treating endometriosis.
[0009] Technical solution: To solve the above-mentioned technical problems, the present invention provides a pharmaceutical composition for treating endometriosis, which contains Cur, EGCG and Pte.
[0010] Preferably, the pharmaceutical composition includes co-delivery liposomes containing curcumin and EGCG, and nanostructured liposomes containing pterostilbene.
[0011] The molar ratio of curcumin to EGCG is 1~4:1~4.
[0012] Preferably, the molar ratio of curcumin to EGCG is 1~2:1~2.
[0013] Preferably, the molar ratio of curcumin to EGCG in the curcumin and EGCG co-delivered liposomes is 1:1.
[0014] The molar ratio of curcumin to pterostilbene is 1~4:1~16.
[0015] The concentration ratio of EGCG, pterostilbene and curcumin is 1~2:4~8:5~10.
[0016] Preferably, the concentration ratio of EGCG, pterostilbene and curcumin is 1~2:4:10.
[0017] The preparation steps of the curcumin and EGCG co-delivery liposomes are as follows: (1) Mix curcumin and EGCG and dissolve them in anhydrous ethanol until completely dissolved; (2) Weigh cholesterol and egg yolk phospholipids and dissolve them in ethyl acetate. Add them to step (1), mix thoroughly and remove the organic solvent to form a uniform film. Then add poloxamer aqueous solution and sonicate to obtain co-delivery liposomes containing curcumin and EGCG.
[0018] (3) When using, add distilled water and stir to suspend, then filter through a 0.45μm microporous membrane to obtain a stable suspension system.
[0019] The total mass of curcumin and EGCG, the molar ratio of cholesterol and egg yolk phospholipids is 1:(1.5~3.5):(1~3).
[0020] Preferably, the molar ratio of curcumin, EGCG, cholesterol, and egg yolk phospholipids is 1:1:7:5.
[0021] The amount of anhydrous ethanol added is 25 to 40 times the total mass of curcumin and EGCG.
[0022] The amount of ethyl acetate added is 20 to 30 times the total mass of curcumin and EGCG.
[0023] The amount of poloxamer aqueous solution added is 20 to 45 times the total mass of curcumin and EGCG.
[0024] The volume of distilled water added during the process is equal to the volume of the poloxamer aqueous solution.
[0025] The preparation steps of the nanostructured liposomes containing pterostilbene are as follows: (1) Weigh out pterostilbene, tristearate and peanut oil, dissolve them in ethyl acetate, and use them as the organic phase; (2) Using poloxamer 188 aqueous solution as the aqueous phase, the aqueous phase was added dropwise to the organic phase under magnetic stirring, and then ultrasonic treatment was performed to remove the organic solvent.
[0026] The molar ratio of the medicinal lipids of pterostilbene to tristearate and peanut oil is 1:15 to 1:25.
[0027] The solid-liquid lipid molar ratio of the tristearate glycerol and peanut oil is 3:1 to 5:1.
[0028] The amount of poloxamer 188 aqueous solution added is 1 to 5 times that of ethyl acetate.
[0029] Preferably, the molar ratio of the pterostilbene to tristearate and peanut oil is 1:15, the molar ratio of the tristearate to peanut oil is 5:1, and the amount of poloxamer aqueous solution added is 1 times that of ethyl acetate in (1).
[0030] The pharmaceutical composition also contains a solvent, including but not limited to pure water or physiological saline.
[0031] The present invention also provides an application of the pharmaceutical composition in the field of biomedicine.
[0032] Curcumin, being a hydrophobic polyphenol, suffers from low water solubility, poor stability, high metabolic rate, rapid clearance, and limited oral bioavailability, which restricts its further clinical application. EGCG, a catechin monomer extracted from green tea, is the main active and water-soluble component of green tea. In vitro, the phenolic hydroxyl groups of EGCG are easily oxidized to form ortho-quinones under the influence of light, oxygen, temperature, and pH, which are highly unstable and subject to degradation during storage, transportation, and processing. In vivo, EGCG has a short retention time in the gastrointestinal tract, low absorption rate, and is easily degraded by body fluids, resulting in low oral bioavailability. Therefore, developing a delivery system capable of simultaneously encapsulating both hydrophilic and hydrophobic substances is novel and beneficial for better leveraging their synergistic effects.
[0033] Liposomes are microcapsules with a lipid bilayer structure that can encapsulate hydrophilic and hydrophobic drug functional factors, reduce the influence of the external environment on the encapsulated substances, improve bioavailability, and enable the encapsulated functional factors to reach the target site more effectively.
[0034] This invention utilizes a thin-film ultrasonic method to construct a liposome system simultaneously encapsulating curcumin and EGCG. The formation of stable inclusion complexes significantly improves the solubility and stability of both substances, thereby enhancing the therapeutic efficacy for endometriosis. By forming inclusion complexes with cholesterol and egg yolk phospholipids, the solubility of curcumin in water is significantly increased. Simultaneously, the formation of these inclusion complexes protects curcumin and EGCG from the effects of light, heat, and oxygen, thereby improving their chemical stability, antioxidant activity, and pharmacological efficacy.
[0035] The solubility of pterostilbene in water is only 0.03 mg / mL, far lower than that of curcumin and EGCG, severely affecting its dissolution. Furthermore, it is easily affected by various enzyme metabolisms in vivo, with an oral bioavailability of only 11.9%, which is unfavorable for clinical application. Therefore, this invention prepares a nanostructured lipid carrier for pterostilbene alone. Due to the introduction of a liquid lipid carrier, it exhibits higher encapsulation efficiency, drug loading capacity, and stability compared to solid lipid nanoparticles. The nanostructured lipid carrier improves the water solubility of pterostilbene, promotes its in vitro drug release, allows it to remain stable in gastrointestinal fluids for a certain period, and reduces the impact of various gastrointestinal enzymes on drug stability, thus facilitating full drug absorption and improving its bioavailability. Simultaneously, the surfactant poloxamer 188 in the formulation also has a positive impact on in vivo drug absorption.
[0036] Epigallocatechin gallate has multiple effects, including inhibiting cell migration and invasion, anti-cancer, antioxidant, and anti-inflammatory properties. In this invention, it mainly functions to inhibit cell migration and invasion.
[0037] Pterostilbene has various effects, including inhibiting cell proliferation, anti-oxidation, anti-inflammation, anti-cancer, anti-diabetic, and anti-obesity. In this invention, it mainly exerts its effect of inhibiting cell proliferation.
[0038] Curcumin has various effects, including anti-inflammatory, antioxidant, anti-proliferative, and anti-angiogenic properties. In this invention, it mainly exerts its effects of anti-angiogenicity, reducing the estrogen sensitivity of ectopic endometrial cells, and decreasing estrogen synthesis.
[0039] This invention reveals the effects of a formulation (EPC05) composed of epigallocatechin gallate, pterostilbene, and curcumin in a specific ratio on three different aspects of endometriosis treatment: invasion and migration, cell proliferation, estrogen synthesis, and sensitivity. Furthermore, process optimization significantly improves bioavailability and absorption efficiency. The research is more detailed, precise, and comprehensive.
[0040] This invention is the first to study the in vitro therapeutic effects and mechanisms of epigallocatechin gallate on human endometriosis cells. Regarding pterostilbene in the treatment of endometriosis, existing research has only been conducted in cell models; this invention is the first to investigate the therapeutic effects of pterostilbene in a mouse model of endometriosis. Regarding curcumin in the treatment of endometriosis, existing research only mentions that curcumin extract can reduce estradiol to inhibit endometriosis, but no publicly available data reveals the relationship between curcumin, estrogen receptors, and endometriosis. This invention is the first to demonstrate that curcumin reduces the sensitivity of endometriosis cells by inhibiting estrogen receptor β levels, thereby inhibiting endometriosis.
[0041] To overcome the aforementioned limitations, this invention innovatively designs a synergistic formulation (EPC05) of curcumin (Cur), epigallocatechin gallate (EGCG), and pterostilbene (Pte). The aim is to achieve a synergistic effect through a triple mechanism: curcumin targets and inhibits estrogen synthesis (CYP19A1 / STAR) and regulates estrogen sensitivity in ectopic cells; EGCG targets and inhibits cell migration and invasion; and pterostilbene targets and inhibits cell proliferation. Based on this, further animal experiments are used to explore the optimal effective ratio and dosage, and the process is explored to effectively improve bioavailability and absorption efficiency, with the goal of providing a highly effective and low-toxicity new treatment strategy for ectopic endocrine disorders (EMs).
[0042] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: 1. This invention significantly improves the solubility of curcumin in water by preparing co-delivery liposomes of curcumin and EGCG. At the same time, the co-delivery liposomes can also protect both from the effects of light, oxygen, temperature and pH, thereby improving their chemical stability and antioxidant activity.
[0043] 2. The nanostructured liposomes prepared by this invention improve the water solubility of pterostilbene, promote its in vitro drug release, increase its in vivo stability, facilitate the full absorption of the drug, improve its bioavailability, and thus enhance its efficacy.
[0044] 3. This invention is the first in China and abroad to combine curcumin, pterostilbene, and EGCG in a specific ratio to improve EMs symptoms in mice with ectopic endometrial cells in vitro and allogeneic endometrial transplantation. It provides a rigorous and comprehensive demonstration of the mechanism by which this drug combination improves key symptoms of EMs. Attached Figure Description
[0045] Figure 1 The effects of different concentrations of EGCG, Cur, and Pte on the viability of 12Z cells were investigated as follows: A. Effect of different concentrations of EGCG on cell viability; B. IC50 of EGCG after 1 day of administration; C. Effect of different concentrations of Pte on cell viability; D. IC50 of Pte after 1 day of administration; E. Effect of different concentrations of Cur on cell viability; F. IC50 of Cur after 1 day of administration. Figure 2 The effects of EGCG on cell migration and invasion: A. Effects of different concentrations of EGCG on cell migration; B. Statistical analysis of cell migration rate results; C. Effects of different concentrations of EGCG on cell invasion; D. Statistical analysis of cell invasion rate results; Figure 3 The effect of Cur on proteins in the estrogen synthesis pathway; Figure 4 The effect of Pte on cell proliferation; Figure 5 The effect of different component ratios of EPC05 on cell proliferation; Figure 6 The effect of different component ratios of EPC05 on cell migration; Figure 7 The effect of different component ratios of EPC05 on cell invasion; Figure 8 The effects of different component ratios of EPC05 on estrogen sensitivity and angiogenic proteins; Figure 9 The effects of different component ratios of EPC05 on proteins in estrogen synthesis and conversion pathways; Figure 10The therapeutic effect of EPC05 on EMs mice (n=3): A. Schematic diagram of EMs mouse modeling; B. Analysis of ectopic lesion infection level; C. Morphological results of lesion sections; D. CD206 detection results of lesion sections; Figure 11 The in vitro drug release curve of Pterocaryonium tumefaciens is shown (n=3). Detailed Implementation
[0046] The technical solution of the present invention will be further described below with reference to the accompanying drawings.
[0047] Table 1 Analytical Instruments
[0048] 2. Reagents: Normal endometrial cells (HEE, catalog number IM-H405) were purchased from Xiamen Yimo Biotechnology Co., Ltd.; ectopic endometrial cells (12Z, catalog number CL-0976) were purchased from Wuhan Pronosei Life Science Co., Ltd.; curcumin (Cur, catalog number HY-N0005) and epigallocatechin gallate (EGCG, catalog number HY-13653) were purchased from Shanghai Haoyuan Biomedical Technology Co., Ltd.; pterostilbene (Pte, catalog number Z-014-210914) was purchased from Shanghai Shidander Standard Technical Service Co., Ltd.; caprylic / capric triglyceride (catalog number 20201003) was purchased from Nan... BOE Pearl Industry & Trade Co., Ltd.; Tristearate (item number 20200509) was purchased from Sinopharm Chemical Reagent Co., Ltd.; Dextran gel (item number Sephadex-G50) was purchased from GE Healthcare, Inc.; CCK8 assay kit (item number C0039) was purchased from Beyotime Biotechnology Co., Ltd.; Transwell chamber (item number 353097) was purchased from Corning Comfort Technology Co., Ltd.; PBS (item number G4202), Crystal Violet (item number G1014), 4% Paraformaldehyde (item number G1101), Electrophoresis buffer (item number G2142), Transfer buffer (item number G2028) Hematoxylin (Catalog No. G1004) and eosin (Catalog No. G1001) were purchased from Savill Biotechnology Co., Ltd.; trypsin (Catalog No. C0201) was purchased from Beyotime Biotechnology Co., Ltd.; complete culture medium (Catalog No. CM-0976) and serum-free culture medium (Catalog No. PM150312) were purchased from Nanjing Yifeixue Biotechnology Co., Ltd.; lysis buffer (Catalog No. P0013) and BCA kit (Catalog No. P0012) were purchased from Beyotime Biotechnology Co., Ltd.; ECL chemiluminescence solution (Catalog No. 180-501) was purchased from Shanghai Tianneng Life Science Co., Ltd.; xylene (Catalog No. A530011) and ethanol (Catalog No. A5) were purchased from Beyotime Biotechnology Co., Ltd. 00737) was purchased from Sangon Biotech Co., Ltd.; neutral resin (item number 10004160) was purchased from Shanghai Hushi Co., Ltd.; VEGFA (item number 66828-1-Ig) was purchased from Wuhan Sanying Biotechnology Co., Ltd.; ER-β (item number ab187291) was purchased from Abokon Trading Co., Ltd.; CYP19A1 (item number 16554-1-AP), STAR (item number 12225-1-AP), GAPDH (item number 60004-1-Ig), CD206 (item number 18704-1-AP), CoraLite488-conjugated Goat Anti-Rabbit IgG (H+L) (item number SA00013-2) was purchased from Wuhan Sanying Biotechnology Co., Ltd.; horseradish peroxidase-labeled goat anti-mouse IgG (H+L) (item number A0216) was purchased from Shanghai Beyotime Biotechnology Co., Ltd.
[0049] Example 1: Exploring the optimal effective concentration of each component
[0050] EGCG was administered alone at five different concentrations: 5 μM, 10 μM, 20 μM, 40 μM, and 80 μM. Pterostilbene was administered alone at five different concentrations: 10 μM, 20 μM, 40 μM, 80 μM, and 160 μM. Curcumin was administered alone at five different concentrations: 5 μM, 10 μM, 20 μM, 40 μM, and 80 μM. Cell viability was assessed using CCK8 assay.
[0051] 1. CCK8 test: (1) Seed HEE or 12Z cell suspension (100 μL / well) into 96-well plates, with 5000 cells per well, and pre-culture the plates in a 37°C, 5% CO2 incubator for 24 h. (2) Add the different test drugs mentioned above to the culture plate respectively; (3) Place the culture plate in an incubator for incubation; (4) Add 10 μL of CCK8 solution to each well; (5) Place the culture plate in an incubator and incubate for 1-4 hours; (6) Measure the absorbance at 450 nm using an enzyme-linked immunosorbent assay (ELISA) reader.
[0052] Implementation results: such as Figure 1 As shown in Figure A, after adding epigallocatechin gallate alone to 12Z cells, on the first day, cell viability did not decrease significantly at 0-40 μM, but decreased significantly at 80 μM. On the second day, cell viability did not decrease significantly at 0-20 μM, but decreased significantly at 40-80 μM. The half-maximal inhibitory concentration (IC50) for cells was 115.1 μM. Figure 1 B); After adding pterostilbene alone, on the first day, cell viability did not decrease significantly at 0-40 μM, but decreased significantly at 80-160 μM. On the second day, cell viability did not decrease significantly at 0-40 μM, but decreased significantly at 80-160 μM. Figure 1 C), the half-maximal inhibitory concentration for cells was 100.9 μM ( Figure 1 D); After adding curcumin alone, on the first day, cell viability did not decrease significantly at 0-20 μM, but decreased significantly at 40-80 μM. On the second day, cell viability did not decrease significantly at 0-10 μM, but decreased significantly at 20-80 μM. Figure 1 E), the half-inhibitory concentration for cells was 50 μM ( Figure 1 F). Therefore, we controlled the final concentration of epigallocatechin gallate to within 20 μM, and selected 5-15 μM for experiments; the concentration of pterostilbene was controlled to within 80 μM, and selected 10-40 μM for experiments; the concentration of curcumin was controlled to within 20 μM, and selected 2.5-15 μM for experiments, to ensure drug safety.
[0053] like Figure 4 As shown, to compare the proliferation of 12Z and HEE cells after the addition of pterostilbene, it was found that the proliferation capacity of HEE cells was significantly weaker than that of 12Z cells when pterostilbene was added alone. Moreover, the proliferation of 12Z cells was significantly inhibited under the action of Pte at concentrations of 80 μM and 160 μM. In order to exert the anti-proliferative effect of pterostilbene, the concentration of pterostilbene was increased to 40-80 μM.
[0054] 2. Analysis of changes in cell migration rate (scratch assay): (1) Marking lines: First, use a needle to evenly mark horizontal lines on the back of the 6-hole plate, about every 2-3 cm, passing through the holes, with 2 lines per hole; (2) Plating: Take one full medium-sized dish cell from Example 1, digest it with trypsin into a single-cell suspension, and inoculate it into a 6-well culture plate; the inoculation principle is that the fusion rate reaches 100% after overnight incubation, and the final total amount of culture medium in each well is 2 mL; (3) Scratches: On the second day, use a 200 μL nozzle to scratch the horizontal lines on the back, parallel or perpendicular to them. The nozzle must be vertical and not tilted. (4) Washing: Add PBS to the adherent cells, shake to wash the cells once, and remove the cells that have been cut off; (5) Take photos under a microscope, ensuring that the scratch is centered and vertical, and that the background is consistent. Samples can be taken at 0, 24, and 48 hours, and photos can be taken in each group of 8 photos.
[0055] like Figure 2 A- Figure 2 As shown in Figure B, the migration rate of 12Z cells was significantly higher than that of HEE cells. After 1 day, the cell migration rate decreased significantly at a concentration of 20 μM EGCG, while there was no significant difference at concentrations of 5 and 10 μM EGCG. After 2 days, the cell migration rate decreased significantly at concentrations of 10 and 20 μM EGCG, while there was no significant difference at a concentration of 5 μM EGCG. This demonstrates that EGCG can inhibit cell migration at concentrations of 10-20 μM.
[0056] 3. Analysis of changes in cell invasion ability (Transwell assay): (1) Preparation of cell suspension: The cells to be tested in Example 1 were cultured to the logarithmic growth phase, digested with 0.25% trypsin for 2-3 min, centrifuged at 1000 rpm for 3 min, the supernatant was discarded after centrifugation, washed with PBS 1-2 times, and then the cells were resuspended in serum-free culture medium; (2) Cell seeding: Add 600 μL of complete culture medium to the lower chamber of a 24-well plate, then use forceps to place the Transwell chamber into the 24-well plate and take a sample containing 1×10⁶ cells. 5The suspension of cells / mL was added to serum-free culture medium to bring the volume up to 200μL, then added to the upper chamber, and finally placed in an incubator for 48h. (3) Cell fixation: On the second day, carefully remove the chamber with tweezers, wash the chamber 3 times with PBS, put the chamber into a new well, add 400 μL of 4% paraformaldehyde, and fix the chamber for 20-30 min. (4) Cell staining: Remove the chamber, wash the chamber 3 times with PBS, place the chamber into a new well, add 400 μL of crystal violet staining solution, and stain for 15-30 min. Remove the crystal violet that has not bound to the cells, and gently wipe the upper side of the chamber with a cotton swab to remove the dye that is not specifically bound to the upper surface of the chamber for subsequent microscopic counting; (5) Cell counting: Take out the chamber, gently soak and wash it several times with water, carefully wipe away the cells on the membrane surface at the bottom of the upper chamber with a wet cotton swab, put the chamber into a new well, heat a little water, take pictures under a microscope, take 5 pictures in each group, count the positive cells that turn purple, and count the results.
[0057] Implementation results: such as Figure 2 C- Figure 2 As shown in Figure D, the invasion rate of 12Z ectopic endometrial cells was significantly higher than that of normal endometrial cells under natural conditions than that of HEE. Cell migration rate was significantly decreased at EGCG concentrations of 5-20 μM. This demonstrates that EGCG can inhibit cell invasion at concentrations of 5-20 μM.
[0058] Therefore, in order to enable EGCG to play a role in inhibiting cell migration and invasion in EPC05, a concentration of 10-20 μM of EGCG was selected in subsequent experiments.
[0059] 4. Analysis of changes in related proteins (immunoblotting): (1) Protein extraction: Take the processed cells, wash them once with PBS, add lysis buffer, scrape the cells off with a scraper, centrifuge at 4°C, and aspirate the supernatant into a 1.5ml EP tube; (2) Protein concentration determination: Using the BCA kit, prepare working solution, add sample, add 200 µl of working solution to each well, incubate at 37℃ for 30 min, detect absorbance with microplate reader, calculate protein concentration, and denature protein at 95℃ for 5 min; (3) Western Blot: Prepare electrophoresis buffer, transfer buffer, and gel. Calculate the loading amount (30 μg / well) according to the sample concentration. Marker (3 μL), electrophoresis at 85V constant voltage until the marker is completely separated, about 30 min. Then switch to 125V constant voltage electrophoresis until the bottom band of the marker is close to the bottom of the gel, about 1 h. PVDF membrane (6×9cm): Immerse in methanol for 30s (to awaken the membrane), wash 3 times with dd H2O, cut a corner as a marker, and immerse in transfer buffer. Place the membrane in the following order from bottom to top: white clamp - sponge - filter paper - PVDF membrane - gel - filter paper - sponge - black clamp, removing all air. Transfer at 300mA for 100min, block with 5% skim milk at room temperature for 2h, cut the desired band, wash the membrane 3 times with TBST for 5min each time, prepare primary antibody according to the instructions, and incubate overnight at 4℃; wash the membrane 3 times with TBST for 5min each time; prepare secondary antibody according to the instructions, and incubate at room temperature for 2h; wash the membrane 3 times with TBST for 5min each time. (4) Exposure and development: Prepare and use immediately. Drop the ECL luminescent liquid onto the membrane, expose it with a gel imaging system and save the image.
[0060] like Figure 3 As shown, the levels of ER-β and VEGFA proteins in 12Z cells were higher than those in HEE cells, but the levels of ER-β and VEGFA proteins decreased after the addition of 5-15 μM curcumin to 12Z cells. Therefore, 5-15 μM curcumin was selected for subsequent experiments.
[0061] Example 2: Efficacy evaluation of EPC05 at different proportions Epigallocatechin gallate, pterostilbene, and curcumin were formulated into groups at different ratios: Group 1: 20 μM, 80 μM, 10 μM; Group 2: 10 μM, 80 μM, 10 μM; Group 3: 20 μM, 40 μM, 10 μM; Group 4: 10 μM, 40 μM, 10 μM; Group 5: 20 μM, 80 μM, 5 μM; Group 6: 20 μM, 80 μM, 15 μM. See Table 2 for details.
[0062] Table 2
[0063] In Table 2, HEE represents normal endometrial cells, and 12Z represents ectopic endometrial cells.
[0064] Cell culture method: Cells were cultured in an incubator at 37°C and 5% CO2. Drug was administered when the cell confluence density reached 80%, and the analysis was performed 24 hours after drug administration.
[0065] The results are as follows Figure 5As shown, after adding different EPC05 ratios, the cell viability of groups 2 and 6 decreased significantly on the first day, and there were significant differences in cell viability among the groups on the second day. To ensure drug safety, groups 1, 2, and 6 were excluded, and groups 3, 4, and 5, which had the least drug toxicity, were selected for subsequent experimental studies.
[0066] The effect of different component ratios on cell migration was determined according to the method in Example 1. The results are as follows: Figure 6 As shown, the cell migration rate in the EPC05-4 drug group was significantly slower than that in the other groups, proving that the drug concentration ratio in the fourth group had the most significant inhibitory effect on cell migration.
[0067] The effect of different component ratios on cell invasion was determined according to the method in Example 1. Figure 7 As shown, the cell invasion rate in the EPC05-4 drug group was significantly slower than that in the other groups, proving that the drug concentration ratio in the fourth group had the most significant inhibitory effect on cell invasion.
[0068] The effects of different component ratios on estrogen sensitivity and angiogenic proteins were determined according to the method in Example 1. Figure 8 As shown, the levels of ER-β and VEGFA proteins in the EPC05-4 group were significantly lower than those in other groups. ER-β is an estrogen receptor and is closely related to estrogen effects, while VEGFA is an angiogenesis-related protein. This demonstrates that the drug concentration ratio in the fourth group had the most significant inhibitory effect on estrogen effects and angiogenesis.
[0069] The effects of different component ratios on proteins involved in estrogen synthesis and conversion pathways were determined using the immunoblotting method described in Example 1. Figure 9 As shown, the STAR and CYP19A1 protein levels in the EPC05-4 drug group were significantly lower than those in other groups. STAR protein regulates estrogen synthesis, and CYP19A1 protein can convert androgens into estrogens, demonstrating that the drug concentration ratio in the fourth group had the most significant inhibitory effect on estrogen synthesis and conversion.
[0070] Example 3: Efficacy evaluation of EPC05 (allogeneic transplant animal experiment) Animal modeling: SPF-grade BALB / C female mice aged 7-8 weeks were selected and injected intraperitoneally with allogeneic mouse uterine fragments ( Figure 10 A).
[0071] 1. Animal experimental protocol:
[0072] Mice that successfully developed the model were divided into three groups: a control group, a model group (MOD), and an EPC05 group (epigallocatechin gallate 10 μM, pterostilbene 40 μM, curcumin 10 μM), with six mice in each group. The EPC05 group was weighed and administered the drugs by gavage once daily at a fixed time for one week. The EPC05 group was administered epigallocatechin gallate 20 mg / kg + pterostilbene 80 mg / kg + curcumin 20 mg / kg daily by gavage. The other groups were weighed and administered an equal volume of physiological saline by gavage at a fixed time daily. On day 8 after drug administration, tissue samples were collected to record the location and size of the ectopic lesions, and the tissues were photographed and fixed in 4% PFA.
[0073] Implementation results: such as Figure 10 As shown in B, the number of ectopic lesions in the EPC05 group was significantly reduced, and the volume of ectopic lesions was also significantly smaller than that in the model group, thus treating the EMs symptoms in the mice.
[0074] Histological observation of endometriotic lesions (HE staining): (1) Tissue sections of ectopic endometrial lesions were placed in a 65℃ oven for dewaxing for 2 hours; (2) Immerse the slices in xylene at 37℃ twice for 15 min each time, immerse the slices in 100% ethanol twice for 2 min each time, 90% ethanol for 2 min, 80% ethanol for 2 min, 70% ethanol for 2 min, and rinse with running water for 10 min. (3) Stain with hematoxylin for 5 min; rinse with running water for 10 min; (4) Differentiate with 1% hydrochloric acid aqueous solution for 30s, then rinse with running water for 10min; (5) Eosin staining for 2.5 min; (6) Immerse the sections in 70% ethanol for 2 min; 80% ethanol for 2 min; 90% ethanol for 2 min; 100% ethanol twice, 2 min each time; xylene, incubate twice, 15 min each time; mount with neutral resin.
[0075] Implementation results: such as Figure 10 As shown in Figure C, in both the model group and the EPC05 group, one or more cystic structures were observed in the ectopic lesions of each group. The structure of each layer of the ectopic lesion was similar to that of the eutopic endometrium. The epithelial cell layer was composed of columnar epithelial cells growing in a ring. Abundant blood vessels were visible in the stromal cell layer, but the number of glands was relatively small or even disappeared, proving that the intraperitoneal injection model was successful.
[0076] 3. Detection of changes in CD206, a marker of M2 macrophages (immunofluorescence assay) Operation example:
[0077] (1) Tissue sections of ectopic endometrial lesions were placed in a 65℃ oven for dewaxing for 2 hours; (2) Immerse the slices in xylene at 37℃ twice for 15 min each time, immerse the slices in 100% ethanol twice for 2 min each time, 90% ethanol for 2 min, 80% ethanol for 2 min, 70% ethanol for 2 min, and rinse with running water for 10 min. (3) 0.5% Triton, 37℃ for 15 min, wash 3 times with PBS, 5 min each time; (4) 2.5% BSA sealed at room temperature for 2 hours; (5) Incubate with primary antibody at 4°C overnight, wash 3 times with PBS, 5 min each time; (6) Incubate the secondary antibody at room temperature in the dark for 2 hours, then wash three times with PBS for 5 minutes each time; (7) Use DAPI to seal the film.
[0078] Experimental results: such as Figure 10 As shown in Figure D, the control group (NC) exhibited weak CD206 fluorescence intensity and low protein expression levels; the model group showed strong CD206 fluorescence intensity and high protein expression levels; and the EPC05 group showed weak CD206 fluorescence intensity and low protein expression levels. CD206 is a highly specific marker of M2 macrophages and is closely related to cell proliferation and metastasis. The results indicate that the endometrial tissue proliferation and metastasis capabilities of normal mice are weak, while those of EMs mice are strong, but these capabilities weaken after administration of EPC05.
[0079] Example 4: Preparation of co-delivery liposomes of curcumin and EGCG using thin-film ultrasonication. Accurately weigh 0.74 g (0.002 mol) of curcumin and 0.46 g (0.001 mol) of EGCG, mix them, and dissolve them in 25 ml of anhydrous ethanol. Sonicate until completely dissolved. Weigh 2.3 g of cholesterol and 1.55 g of egg yolk phospholipids, dissolve them in 15 ml of ethyl acetate, mix them thoroughly with the cholesterol, and then remove the organic solvent by rotary evaporation in a 40°C constant temperature water bath, allowing the film-forming material to form a uniform film on the bottle wall. Add 20 ml of 1.0% poloxamer 188 aqueous solution, sonicate for 40 min, and obtain the co-delivery liposomes of curcumin and EGCG. Solidify them in a refrigerator at 4°C and store for later use. When needed, add distilled water to 20 mL, filter through a 0.45 μm microporous membrane, and obtain a stable suspension system.
[0080] Example 5: Preparation of co-delivery liposomes of curcumin and EGCG using thin-film ultrasonication. Accurately weigh 0.37 g (0.001 mol) of curcumin and 0.46 g (0.001 mol) of EGCG, mix them, and dissolve them in 30 ml of anhydrous ethanol. Sonicate until completely dissolved. Weigh 1.55 g of cholesterol and 0.77 g of egg yolk phospholipids, dissolve them in 20 ml of ethyl acetate, mix them thoroughly with the cholesterol, and then remove the organic solvent by rotary evaporation in a 40°C constant temperature water bath, allowing the film-forming material to form a uniform film on the bottle wall. Add 30 ml of 1.0% poloxamer 188 aqueous solution, sonicate for 40 min, and obtain the co-delivery liposomes of curcumin and EGCG. Solidify them in a refrigerator at 4°C and store for later use. When needed, add distilled water to 30 mL, filter through a 0.45 μm microporous membrane, and obtain a stable suspension system.
[0081] Example 6: Preparation of co-delivery liposomes of curcumin and EGCG using thin-film ultrasonication.
[0082] Accurately weigh 0.37 g (0.001 mol) of curcumin and 0.92 g (0.002 mol) of EGCG, mix them, and dissolve them in 35 ml of anhydrous ethanol. Sonicate until completely dissolved. Weigh 3.1 g of cholesterol and 1.16 g of egg yolk phospholipids, dissolve them in 25 ml of ethyl acetate, mix them thoroughly with the cholesterol, and then remove the organic solvent by rotary evaporation in a 40°C constant temperature water bath, allowing the film-forming material to form a uniform film on the bottle wall. Add 40 ml of 1.0% poloxamer 188 aqueous solution, sonicate for 40 min, and obtain the co-delivery liposomes of curcumin and EGCG. Solidify them in a refrigerator at 4°C and store for later use. When needed, add distilled water to 40 mL, filter through a 0.45 μm microporous membrane, and obtain a stable suspension system.
[0083] Example 7: Preparation of Pterostilbene nanostructured liposomes by solvent evaporation method
[0084] Weigh 0.2g of pterostilbene raw material, 1.25g of peanut oil, and 3.75g of tristearate glyceryl ester, and dissolve them in 20mL of ethyl acetate as the organic phase. Weigh an appropriate amount of poloxamer 188 and prepare 100mL of a 1.0% aqueous solution as the aqueous phase (40℃). Add the aqueous phase dropwise to the organic phase under magnetic stirring. After the addition is complete, sonicate (power 250W, working for 2s every 2s) for 20min. Remove the organic solvent under vacuum in a rotary evaporator at 40℃, concentrate to 20mL, and place in a refrigerator to solidify. When using, add distilled water to 60mL and filter through a 0.45μm microporous membrane to obtain a stable suspension system.
[0085] Example 8: Preparation of Pterostilbene nanostructured liposomes by solvent evaporation method
[0086] Weigh 0.81g of pterostilbene raw material, 3.24g of peanut oil, and 12.96g of tristearate glyceryl ester, and dissolve them in 40mL of ethyl acetate as the organic phase. Weigh an appropriate amount of poloxamer 188 and prepare 100mL of a 1.1% aqueous solution as the aqueous phase (40℃). Add the aqueous phase dropwise to the organic phase under magnetic stirring. After the addition is complete, sonicate (power 250W, working for 2s every 2s) for 20min. Remove the organic solvent under vacuum in a rotary evaporator at 40℃, concentrate to 40mL, and place in a refrigerator to solidify. When using, add distilled water to 60mL and filter through a 0.45μm microporous membrane to obtain a stable suspension system.
[0087] Example 9: Preparation of Pterostilbene nanostructured liposomes by solvent evaporation method
[0088] Weigh 2g of pterostilbene raw material, 5g of peanut oil, and 25g of tristearate glyceryl ester, and dissolve them in 60mL of ethyl acetate as the organic phase. Weigh an appropriate amount of poloxamer 188 and prepare 100mL of a 1.25% aqueous solution as the aqueous phase (40℃). Add the aqueous phase dropwise to the organic phase under magnetic stirring. After the addition is complete, sonicate (power 250W, working for 2s every 2s) for 20min. Remove the organic solvent under vacuum in a rotary evaporator at 40℃, concentrate to 50mL, and place in a refrigerator to solidify. When using, add distilled water to 60mL and filter through a 0.45μm microporous membrane to obtain a stable suspension system.
[0089] Example 10
[0090] A composition for treating endometriosis includes the following ingredients: curcumin and EGCG co-delivery liposomes, pterostilbene nanostructured lipocarrier, and purified water; The molar ratio of curcumin to EGCG in the curcumin and EGCG co-delivery liposomes is 1:1. The amount (molar ratio) of pterostilbene in the pterostilbene nanostructure lipid carrier is 4 times that of curcumin.
[0091] The curcumin and EGCG co-delivered liposomes used were obtained in Example 5; the pterostilbene nanostructured liposomes used were obtained in Example 9.
[0092] Example 11
[0093] A composition for treating endometriosis includes the following ingredients: curcumin and EGCG co-delivery liposomes, pterostilbene nanostructured lipocarrier, and purified water; The molar ratio of curcumin to EGCG in the curcumin and EGCG co-delivery liposome is 2:3; The amount (molar ratio) of pterostilbene in the pterostilbene nanostructure lipid carrier is twice that of curcumin.
[0094] The curcumin and EGCG co-delivered liposomes used were obtained in Example 5; the pterostilbene nanostructured liposomes used were obtained in Example 8.
[0095] Example 12 A composition for treating endometriosis includes the following ingredients: curcumin and EGCG co-delivery liposomes, pterostilbene nanostructured lipocarrier, and purified water; The molar ratio of curcumin to EGCG in the curcumin and EGCG co-delivery liposome is 1:4; The amount of pterostilbene in the pterostilbene nanostructure lipid carrier is 1 times that of curcumin.
[0096] The curcumin and EGCG co-delivered liposomes used were obtained in Example 4; the pterostilbene nanostructured liposomes used were obtained in Example 7.
[0097] Example 13 Performance Testing 1. The following tests were performed on the co-delivery liposomes of curcumin and EGCG prepared in Examples 4-6: (1) Test of encapsulation rate and drug loading of curcumin and EGCG: The content of curcumin and EGCG in compound liposomes was determined by HPLC.
[0098] Chromatographic conditions: Column: Agilent ZORBAX SB-C 18 (250 mm×4.6 mm id, 5μm) and Agilent Zorbax SB-C 18 Guard column (12.5 mm × 4.6 mm, id, 5 μm). Mobile phase: acetonitrile-0.3% glacial acetic acid aqueous solution (80:20); column temperature: 30℃; flow rate: 1.0 ml / min; EGCG content was detected at 280 nm wavelength, and curcumin content was detected at 425 nm wavelength; injection volume: 10 μL.
[0099] Accurately pipette 0.5 ml of each liposome suspension system prepared in Examples 4-6 onto a G50 column of dextran gel, elute with 50 ml of distilled water, and dilute to volume with methanol to obtain Sample 1. Separately, dissolve equal amounts of curcumin and EGCG contained in 0.5 ml of each liposome suspension system from Examples 4-6 in methanol and dilute to volume with methanol to obtain Sample 2. After filtration, inject 10 μL of each sample, and calculate the total content of curcumin and EGCG in Sample 1 and Sample 2 using the external standard method, denoted as W. 样1 and W 样2 The embedding rate is calculated using the following formula: Embedding rate = W 样1 / W 样2 ×100% Drug loading capacity is calculated using the following formula: Drug loading = W 样1 / (W 蛋黄磷脂 +W 胆固醇 )×100%.
[0100] Among them W 蛋黄磷脂 W 胆固醇 These refer to the quality of egg yolk phospholipids and cholesterol, respectively.
[0101] The specific test results are shown in Table 3.
[0102] Table 3. Trait parameters of co-delivered liposomes of curcumin and EGCG
[0103] (2) Stability: The liposome suspension system in Example 6 was stored in a light-protected, sealed container at 4°C for 15 days. Samples were taken out at 0, 1, 3, 7, 11, and 15 days, and particle size, polydispersity index, and zeta potential were measured in triplicate at each time point. The results are shown in Table 4. Changes in the liposomes were observed, and the results showed that the liposome system did not change significantly over time, and its appearance did not change significantly after storage, indicating good stability.
[0104] Table 4. Storage stability of co-delivered liposomes of curcumin and EGCG
[0105] 2. The following tests were performed on the pterostilbene nanostructured liposomes of Examples 7-9: (1) Test of Pterostilbene encapsulation rate and drug loading: The content of Pterostilbene in the nanostructured liposomes was determined by HPLC.
[0106] Chromatographic conditions: Agilent ZORBAX SB-C 18 (250 mm × 4.6 mm id, 5 μm) and Agilent Zorbax SB-C 18 Guard column (12.5 mm × 4.6 mm, id, 5 μm). Mobile phase: acetonitrile-water (60:40), flow rate: 1.0 mL / min; column temperature: 30 °C; detection wavelength: 306 nm.
[0107] Take 1 mL of the nanostructured lipid carrier suspension, sonicate with 10 mL of acetonitrile for 5 min, and then dilute to 100 mL. Mix well, transfer 5 mL to a 10 mL volumetric flask, and dilute to the mark with the mobile phase to prepare the test solution for determining the total amount of pterostilbene m. 总药量Take another 1 mL and transfer it to an ultrafiltration tube (molecular weight cutoff 8000~12000 Da), place it in a high-speed centrifuge at 4 ℃, centrifuge at 8500 r / min for 10 min, collect the filtrate, and determine the free amount of pterostilbene (m). 游离 The encapsulation efficiency and drug loading are calculated using the following formulas: Encapsulation efficiency = [(m 总药量 -m 游离 ) / m 总药量 ]×100%, Drug loading = [ (m 总药量 - m 游离 ) / m 总 ]×100%, where m 总 The total dosage of drugs and lipids is shown in Table 5.
[0108] Table 5. Shape parameters of pterostilbene nanostructured liposomes
[0109] (2) In vitro drug release study: Pterostilbene, a physical mixture (drug and excipient ratios were the same as for nanostructured liposomes), and an appropriate amount of nanostructured liposomes were added to distilled water (the mass concentration of pterostilbene was 10 mg / mL). 2 mL of this mixture was transferred to a dialysis bag (molecular weight cutoff 8000~14000 Da). The drug release medium was set to 1000 mL of 1.0% SDS solution, the medium temperature was (37±1)℃, and the stirring speed was 75 r / min. 4 mL of the mixture was taken at 0, 0.5, 1, 1.5, 2, 4, 8, 16, 24, 36, and 48 h, and 4 mL of 1.0% SDS solution was immediately added. The mixture was filtered through a 0.45 μm aqueous microporous membrane. The filtrate was then injected and analyzed under the above chromatographic conditions. The cumulative release rate was calculated, and the results are shown in the figure. Figure 11 The in vitro drug release of the active pharmaceutical ingredient and the physical mixture was found to be basically the same, while the cumulative release rate of the nanostructured lipid carrier lyophilized powder was significantly higher than that of the other two at different time points, reaching 79.8% within 48 hours.
Claims
1. A pharmaceutical composition for treating endometriosis, characterized in that, It contains 10 μM curcumin, 10 μM MEGCG and 40 μM pterostilbene.
2. The pharmaceutical composition according to claim 1, characterized in that, The curcumin and EGCG are co-delivery liposomes containing curcumin and EGCG; the pterostilbene is a nanostructured liposome containing pterostilbene.
3. The pharmaceutical composition according to claim 2, characterized in that, The preparation steps of the curcumin and EGCG co-delivery liposomes are as follows: (1) Mix curcumin and EGCG and dissolve them in anhydrous ethanol until completely dissolved; (2) Weigh cholesterol and egg yolk phospholipids and dissolve them in ethyl acetate. Add them to step (1), mix thoroughly and remove the organic solvent to form a uniform film. Then add poloxamer aqueous solution and sonicate to obtain co-delivery liposomes containing curcumin and EGCG.
4. The pharmaceutical composition according to claim 2, characterized in that, The preparation steps of the nanostructured liposomes containing pterostilbene are as follows: (1) Weigh out pterostilbene, tristearate and peanut oil, dissolve them in ethyl acetate, and use them as the organic phase; (2) Using poloxamer 188 aqueous solution as the aqueous phase, the aqueous phase was added dropwise to the organic phase under magnetic stirring, and then ultrasonic treatment was performed to remove the organic solvent.
5. The pharmaceutical composition according to claim 4, characterized in that, The molar ratio of pterostilbene to tristearate and peanut oil is 1:15 to 1:
25.
6. The composition according to claim 4, characterized in that, The solid-liquid lipid molar ratio of the tristearate glycerol and peanut oil is 3:1 to 5:
1.
7. The pharmaceutical composition according to claim 4, characterized in that, The amount of poloxamer 188 aqueous solution added is 1 to 5 times that of ethyl acetate.
Citation Information
Patent Citations
Contactor with readily accessible wire connecting terminals disposed at different levels
EP0000711A1
Method of treating endometriosis experimentally in rats
RU2846948C1
